Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

15.29USD
4:21pm BST
Change (% chg)

$-0.05 (-0.33%)
Prev Close
$15.34
Open
$15.47
Day's High
$15.70
Day's Low
$15.04
Volume
17,889
Avg. Vol
93,175
52-wk High
$26.49
52-wk Low
$5.62

Summary

Name Age Since Current Position

Paul Manning

63 2017 Chairman of the Board

David Zaccardelli

55 2018 President, Chief Executive Officer

Mark Hahn

56 2018 Chief Financial Officer

Kevin Laliberte

41 2017 Senior Vice President - Product Development

Lee Allen

67 2017 Chief Medical Officer

Jason Hoitt

41 2018 Chief Commercial Officer

Sean Stalfort

49 2016 Director

Steven Goldman

67 2017 Independent Director

Roger Jeffs

57 2017 Independent Director

Alfred Novak

71 2017 Independent Director

Nancy Wysenski

61 2018 Independent Director

Biographies

Name Description

Paul Manning

Mr. Paul B. Manning is Chairman of the Board of the company. Mr. Manning has served as the Chairman of our Board of Directors since June 2017 and as a member of our Board of Directors since September 2016. Mr. Manning is the Chairman and Chief Executive Officer of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, which he founded in 2010. Prior to that, Mr. Manning founded PBM Products in 1997, a producer of infant formula and baby food, which was sold to Perrigo Corporation in 2010. Mr. Manning is a director of Verrica Pharmaceuticals Inc., as well as various private companies, and was previously on the Board of Directors of AveXis, Inc., Perrigo Corporation and Concordia Healthcare Corp. Mr. Manning received a B.S. in microbiology from the University of Massachusetts. Our Board of Directors believes that Mr. Manning should serve as a director based upon on his over 30 years of managerial and operational experience in the healthcare industry and as an investor in healthcare related companies.

David Zaccardelli

Dr. David Zaccardelli Pharm.D. is President, Chief Executive Officer of the company. Dr. Zaccardelli has served as our President and Chief Executive Officer since December 2018. Prior to joining us, Dr. Zaccardelli served as the acting Chief Executive Officer of Cempra Pharmaceuticals, Inc. from December 2016 until the company's merger with Melinta Therapeutics, Inc in November 2017. From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics Corporation, including chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations. Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He also served as director of clinical and scientific affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli currently serves on the Board of Directors of Melinta Therapeutics, Inc. as well as several private healthcare companies. Dr. Zaccardelli received a Pharm.D. from the University of Michigan and completed a Fellowship in Clinical Research and Drug Development at the University of North Carolina and Burroughs Wellcome & Co. Our Board of Directors believes that Dr. Zaccardelli should serve as a director based on his leadership of our company as the President and Chief Executive Officer and his substantial specialty pharmaceutical executive leadership and operational expertise. `

Mark Hahn

Mr. Mark W. Hahn is Chief Financial Officer of the company. Mr. Hahn has served as our Chief Financial Officer since January 2018. Mr. Hahn was previously the executive vice president and chief financial officer of Cempra, Inc., a clinical-stage pharmaceutical company, from February 2010 to November 2017. From 2008 to 2009, Mr. Hahn was the chief financial officer of Athenix Corp., an agricultural biotechnology company, leading its merger with Bayer CropScience, where he served as finance director into 2010. Prior to Athenix, Mr. Hahn was the chief financial officer of various companies including GigaBeam Corporation, a telecommunications equipment company, BuildLinks, Inc. and PerformaWorks, Inc., software companies, and Charles & Colvard, Ltd., a consumer products company. Mr. Hahn began his career at Ernst & Young where he served in various capacities, culminating in senior manager from 1984 until 1996. Mr. Hahn holds a B.B.A. in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in the State of Maryland and North Carolina.

Kevin Laliberte

Dr. Kevin Laliberte is Senior Vice President - Product Development of the company. Dr. Laliberte has served as our Senior Vice President, Product Development since March 2017. From 2003 to March 2017, Dr. Laliberte held various positions at United Therapeutics Corporation, including as the Senior Vice President, Product Development and Clinical Operations from March 2015 to March 2017, as the Associate Vice President Product Development from March 2013 to February 2015 and as the Senior Director Product Development from 2010 to March 2013. Dr. Laliberte holds a Pharm.D. from the University of Michigan and completed a Drug Development and Clinical Research Fellowship at the University of North Carolina School of Pharmacy and GlaxoSmithKline.

Lee Allen

Dr. Lee F. Allen, M.D., Ph.D. is Chief Medical Officer of the company. Dr. Allen has served as our Chief Medical Officer since April 2017. From January 2016 to April 2017, Dr. Allen served as Chief Medical Officer managing Clinical Development, Medical Affairs and Regulatory Affairs at Argos Therapeutics. Dr. Allen served as Chief Medical Officer at Spectrum Pharmaceuticals from March 2013 to January 2016. From August 2007 to March 2013, Dr. Allen served as Chief Medical Officer at AMAG Pharmaceuticals. From 2003 through 2007, Dr. Allen served as the Clinical Site Head and Global Oncology Therapeutic Area Director for Wyeth Pharmaceuticals' research and development site in Cambridge, MA. From 1999 to 2003, Dr. Allen helped establish Oncology as a new therapeutic area at Pfizer and served as Executive Director and Site Therapeutic Area Leader for the Ann Arbor Oncology portfolio. Dr. Allen holds a Ph.D. and M.D. from the Rutgers Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey), and completed Residency training in Internal Medicine and Fellowship training in Hematology and Oncology at the Duke University Medical Center. As a postdoc, Dr. Allen investigated signal transduction pathways at Duke in the Howard Hughes Laboratory of Nobel Laureate, Dr. Robert Lefkowitz, and has authored or co-authored more than 50 publications.

Jason Hoitt

Mr. Jason Hoitt is Chief Commercial Officer of the company. Mr. Hoitt has served as our Chief Commercial Officer since December 2018. From May 2017 to December 2018, Mr. Hoitt was the Vice President, Head of US Sales, at Insmed Inc. From 2013 to May 2017, Mr. Hoitt held various leadership roles in Medical Affairs and US Sales at Sarepta Therapeutics. From 2010 to 2013, Mr. Hoitt held senior positions in both marketing and sales at Vertex Pharmaceuticals. From 2004 to 2010, Mr. Hoitt held various positions at Gilead Sciences. Mr. Hoitt began his career in 1999 as a bench researcher at Boston's New England Medical Center, Tufts Medical School, which led to biopharmaceutical roles at AstraZeneca and Schering Oncology-Biotech. Mr. Hoitt holds a B.A. in Spanish from the College of the Holy Cross in Worcester, MA.

Sean Stalfort

Mr. Sean Stalfort is Director of the Company. Mr. Stalfort has served as a member of our Board of Directors since September 2016. Mr. Stalfort is the President of PBM Capital Group, LLC, a private equity investment firm in the business of investing in healthcare and life-science related companies, and has worked at PBM Capital Group, LLC since 2010. Prior to joining PBM Capital Group, LLC, Mr. Stalfort was the Executive Vice President for New Business Development/M&A for PBM Products. Mr. Stalfort is also a founding Partner of Octagon Partners and Octagon Finance, historic tax credit real estate companies. Mr. Stalfort is a director of Verrica Pharmaceuticals Inc., as well as several private healthcare companies. Mr. Stalfort also served as our President from April 2016 until December 2016. Mr. Stalfort received a B.A. in Business Economics and Political Science from Brown University. Our Board of Directors believes that Mr. Stalfort should serve as a director based upon on his years as an investor in healthcare related companies.

Steven Goldman

Mr. Steven M. Goldman is Independent Director of the company. Mr. Goldman has served as a member of our Board of Directors since May 2017. Mr. Goldman has been a Partner of Kramer Levin Naftalis & Frankel LLP since 2009. Mr. Goldman specializes in mergers and acquisitions, financings, joint ventures, private placements, leveraged buyouts and general corporate counseling. He has represented numerous banks in connection with financing of acquisitions and recapitalizations, and insurance brokerages in connection with regulatory enforcement issues and in purchase and sale transactions. From 2006 to 2009, before joining Kramer Levin, Mr. Goldman was the State of New Jersey's Department of Banking and Insurance Commissioner, appointed by Governor Jon S. Corzine. In that role, Mr. Goldman chaired the Reinsurance Task Force at the National Association of Insurance Commissioners which completed a framework for modernizing the regulation of reinsurance in the United States and between the United States and other countries. Mr. Goldman has served as a director of Bank Leumi USA since May 2015. Mr. Goldman also served as a Director of ConnectOne Bank and ConnectOne Bancorp, Inc from 2011 to 2014. He also Chaired the International Insurance Relations Committee of the NAIC, and the Reinsurance and other Forms of Risk Transfer Subcommittee on behalf of the United States at the International Association of Insurance Supervisors from 2007 to 2009. Mr. Goldman has testified before Congress on multiple occasions regarding insurance regulation and health care reform. Mr. Goldman is on the Dean's Board of Advisors for The George Washington University Law School, is a Member of the Bar in New York and New Jersey and is currently the Chair of the Operations and Finance Committee, a member of the Executive Committee, and Assistant Treasurer of the New Jersey Performing Arts Center and a member of the Board of Managers of Theatre Square Development Company.

Roger Jeffs

Dr. Roger A. Jeffs is Independent Director of the company. Dr. Jeffs has served as a member of our Board of Directors since May 2017. Dr. Jeffs retired as President and Co-Chief Executive Officer of United Therapeutics Corporation in June 2016. Prior to his retirement, Dr. Jeffs served as the Co-Chief Executive Officer of United Therapeutics Corporation from January 2015 to June 2016 and President of United Therapeutics Corporation from 2001 to June 2016. Dr. Jeffs joined United Therapeutics Corporation in 1998 as Director of Research, Development and Medical and also served as its Chief Operating Officer from 2001 to 2014. Prior to 1998, Dr. Jeffs worked at Amgen, Inc. as Manager of Clinical Affairs and Associate Director of Clinical Research from 1995 to 1998. Dr. Jeffs served as a Director of United Therapeutics Corporation from 2001 until June 2016, and currently serves on the Board of Directors of Albireo Pharma, Inc., Axsome Therapeutics, Sangamo Therapeutics and Axovant Sciences Ltd. Dr. Jeffs is the Lead Director of Axsome Therapeutics. Dr. Jeffs holds a B.S. in Chemistry from Duke University and Ph.D. in Pharmacology from the University of North Carolina. Our Board of Directors believes that Dr. Jeffs should serve as a director based on his scientific background and business experience, coupled with his experience as a Chief Executive Officer of a publicly-traded biotechnology company.

Alfred Novak

Mr. Alfred J. Novak is Independent Director of the Company. Mr. Novak has served as a member of our Board of Directors since May 2017. Mr. Novak has served on the board of LivaNova, a global medical device company since October 2015. From 2007 until October 2015, Mr. Novak served on the board of Cyberonics, until its merger with Sorin S.p.a. to form LivaNova. From April 2014 until March 2015, Mr. Novak served as President and Chief Executive Officer of Syntheon Cardiology, LLC, an early-stage company developing a percutaneous prosthetic aortic heart valve. From 1999 until January 2014, he served on the Board of Directors of OrbusNeich Medical Technology Company, Ltd., a privately held interventional cardiology company, where he was Chairman and Chief Executive Officer from 2010 until 2013. In 1998, he was a founder of Syntheon, LLC, a privately held company that focused on minimally invasive medical devices for the gastroenterology and vascular markets. From 2002 until 2006, Mr. Novak was the President, Chief Executive Officer and a director of Novoste Corporation, a publicly held interventional cardiology company. Mr. Novak received an M.B.A. from the Wharton School, University of Pennsylvania, and a B.S. in Marine Transportation from the United States Merchant Marine Academy. Our Board of Directors believes that Mr. Novak should serve as a director based on his broad operating executive experience as Chief Executive Officer and Chief Financial Officer at medical device companies, his board of director experience at medical device companies, his expertise concerning new product development, regulatory approval and commercialization of medical devices and his finance and accounting expertise.

Nancy Wysenski

Ms. Nancy J. Wysenski is Independent Director of the company. Ms. Wysenski has served as a member of our Board of Directors since June 2018. Ms. Wysenski is currently a member of the Board of Directors of Alkermes Pharmaceuticals and Tetraphase Pharmaceuticals. From December 2009 through June 2012, Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals. Prior to joining Vertex, she served as Chief Operating Officer of Endo Pharmaceuticals, where she led sales, marketing, commercial operations, supply chain management, human resources, and various business development initiatives. Prior to her role at Endo Pharmaceuticals, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. Before joining EMD Pharmaceuticals, she held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski received her BSN in Nursing from Kent State University and her M.B.A. from Baldwin-Wallace College. Our Board of Directors believes that Ms. Wysenski should serve as a director based on her broad operating experience and expertise in the healthcare sector.

Basic Compensation

Name Fiscal Year Total

Paul Manning

--

David Zaccardelli

4,376,860

Mark Hahn

5,107,440

Kevin Laliberte

1,428,230

Lee Allen

1,968,540

Jason Hoitt

--

Sean Stalfort

--

Steven Goldman

234,095

Roger Jeffs

229,095

Alfred Novak

229,095

Nancy Wysenski

648,444
As Of  31 Dec 2018